Low Mechanical Index Contrast Mode Versus High Mechanical Index Contrast Mode: Which is a More Sensitive Method for Detecting Sonazoid Microbubbles in the Liver of Normal Subjects?

Overview

Journal J Med Ultrason (2001)

Specialty Radiology

Date 2016 Apr 2

PMID 27033867

Citations 5

Authors

Hiromi Nihonmatsu

Kazushi Numata

Hiroyuki Fukuda

Katsuaki Tanaka

Mari Ooba

Shin Maeda

Affiliations

Soon will be listed here.

Abstract

Purpose: Using the low mechanical index (MI) contrast mode and the high MI contrast mode of contrast-enhanced ultrasonography, we evaluated which method is more sensitive for detecting Sonazoid microbubbles in the liver of normal subjects.

Methods: Thirteen normal subjects received an intravenous bolus injection of 0.2 mL of Sonazoid. We defined the intensity difference as the intensity post-injection minus the intensity pre-injection. We evaluated the intensity difference at the portal vein using both the low MI (0.21-0.23) and the high MI (0.7-1.2) at 1 min, at every 10 min between 10 to 60 min, and at every 30 min between 60 to 300 min post-injection. The intensity difference at the liver parenchyma was also evaluated at eight points (1, 10, 30, 60, 120, 180, 240, and 300 min) using the low MI and at three points (1, 10, and 300 min) using the high MI.

Results: The intensity differences at the portal vein measured using high MI were significantly higher than those measured using the low MI at each point between 1 and 240 min (P < 0.01) and at 270 min post-injection (P < 0.05). The intensity differences at the liver parenchyma measured using the high MI were also significantly higher than those measured using the low MI at each time point (P < 0.01).

Conclusion: Compared with the low MI, the high MI is more sensitive for detecting Sonazoid microbubbles in the liver of normal subjects.

Citing Articles

The Role of Molecular Imaging in Personalized Medicine.

Salih S, Elliyanti A, Alkatheeri A, AlYafei F, Almarri B, Khan H J Pers Med. 2023; 13(2).

PMID: 36836603 PMC: 9959741. DOI: 10.3390/jpm13020369.

The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid.

Lee J, Minami Y, Choi B, Lee W, Chou Y, Jeong W J Med Ultrasound. 2020; 28(2):59-82.

PMID: 32874864 PMC: 7446696. DOI: 10.4103/JMU.JMU_124_19.

The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid.

Lee J, Minami Y, Choi B, Lee W, Chou Y, Jeong W Ultrasonography. 2020; 39(3):191-220.

PMID: 32447876 PMC: 7315291. DOI: 10.14366/usg.20057.

Application of new ultrasound techniques for focal liver lesions.

Wang F, Numata K, Nihonmatsu H, Okada M, Maeda S J Med Ultrason (2001). 2020; 47(2):215-237.

PMID: 31950396 DOI: 10.1007/s10396-019-01001-w.

Safety of Perfluorobutane (Sonazoid) in Characterizing Focal Liver Lesions.

Chou Y, Liang J, Wang S, Hsu S, Hu J, Yang S J Med Ultrasound. 2019; 27(2):81-85.

PMID: 31316217 PMC: 6607878. DOI: 10.4103/JMU.JMU_44_19.

References

Numata K, Tanaka K, Kiba T, Mitsui K, Saito S, Sekihara H . Hemodynamic changes in hepatic artery after glucose ingestion in healthy subjects and patients with cirrhosis. J Clin Ultrasound. 1998; 26(3):137-42. DOI: 10.1002/(sici)1097-0096(199803/04)26:3<137::aid-jcu5>3.0.co;2-n. View

Numata K, Luo W, Morimoto M, Kondo M, Kunishi Y, Sasaki T . Contrast enhanced ultrasound of hepatocellular carcinoma. World J Radiol. 2010; 2(2):68-82. PMC: 2998925. DOI: 10.4329/wjr.v2.i2.68. View

Takizawa K, Numata K, Morimoto M, Kondo M, Nozaki A, Moriya S . Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur J Radiol. 2013; 82(9):1471-80. DOI: 10.1016/j.ejrad.2013.04.045. View

Moriyasu F, Itoh K . Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 2009; 193(1):86-95. DOI: 10.2214/AJR.08.1618. View

Alzaraa A, Gravante G, Chung W, Al-Leswas D, Morgan B, Dennison A . Contrast-enhanced ultrasound in the preoperative, intraoperative and postoperative assessment of liver lesions. Hepatol Res. 2013; 43(8):809-19. DOI: 10.1111/hepr.12044. View

Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H . Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol. 2007; 33(2):318-25. DOI: 10.1016/j.ultrasmedbio.2006.08.008. View

Luo W, Numata K, Morimoto M, Nozaki A, Nagano Y, Sugimori K . Clinical utility of contrast-enhanced three-dimensional ultrasound imaging with Sonazoid: findings on hepatocellular carcinoma lesions. Eur J Radiol. 2008; 72(3):425-31. DOI: 10.1016/j.ejrad.2008.09.003. View

Skyba D, Price R, Linka A, Skalak T, Kaul S . Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. Circulation. 1998; 98(4):290-3. DOI: 10.1161/01.cir.98.4.290. View

Watanabe R, Matsumura M, Chen C, Kaneda Y, Fujimaki M . Characterization of tumor imaging with microbubble-based ultrasound contrast agent, sonazoid, in rabbit liver. Biol Pharm Bull. 2005; 28(6):972-7. DOI: 10.1248/bpb.28.972. View

10.

Toft K, Hustvedt S, Hals P, Oulie I, Uran S, Landmark K . Disposition of perfluorobutane in rats after intravenous injection of Sonazoid. Ultrasound Med Biol. 2005; 32(1):107-14. DOI: 10.1016/j.ultrasmedbio.2005.09.008. View

11.

Sontum P . Physicochemical characteristics of Sonazoid, a new contrast agent for ultrasound imaging. Ultrasound Med Biol. 2008; 34(5):824-33. DOI: 10.1016/j.ultrasmedbio.2007.11.006. View

12.

Kindberg G, Tolleshaug H, Roos N, Skotland T . Hepatic clearance of Sonazoid perfluorobutane microbubbles by Kupffer cells does not reduce the ability of liver to phagocytose or degrade albumin microspheres. Cell Tissue Res. 2003; 312(1):49-54. DOI: 10.1007/s00441-003-0698-0. View

13.

Claudon M, Dietrich C, Choi B, Cosgrove D, Kudo M, Nolsoe C . Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2012; 39(2):187-210. DOI: 10.1016/j.ultrasmedbio.2012.09.002. View

14.

Tanaka H, Iijima H, Higashiura A, Yoh K, Ishii A, Takashima T . New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography. J Gastroenterol. 2013; 49(4):755-63. DOI: 10.1007/s00535-013-0830-1. View

15.

Numata K, Morimoto M, Ogura T, Sugimori K, Takebayashi S, Okada M . Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography. J Ultrasound Med. 2008; 27(3):395-406. DOI: 10.7863/jum.2008.27.3.395. View

16.

Luo W, Numata K, Kondo M, Morimoto M, Sugimori K, Hirasawa K . Sonazoid-enhanced ultrasonography for evaluation of the enhancement patterns of focal liver tumors in the late phase by intermittent imaging with a high mechanical index. J Ultrasound Med. 2009; 28(4):439-48. DOI: 10.7863/jum.2009.28.4.439. View

17.

Kong W, Wang W, Huang B, Ding H, Mao F . Value of wash-in and wash-out time in the diagnosis between hepatocellular carcinoma and other hepatic nodules with similar vascular pattern on contrast-enhanced ultrasound. J Gastroenterol Hepatol. 2013; 29(3):576-80. DOI: 10.1111/jgh.12394. View

18.

Numata K, Fukuda H, Miwa H, Ishii T, Moriya S, Kondo M . Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma. Eur J Radiol. 2013; 83(1):95-102. DOI: 10.1016/j.ejrad.2013.09.025. View

19.

Maruyama H, Takahashi M, Shimada T, Sekimoto T, Kamesaki H, Kanai F . Pretreatment microbubble-induced enhancement in hepatocellular carcinoma predicts intrahepatic distant recurrence after radiofrequency ablation. AJR Am J Roentgenol. 2013; 200(3):570-7. DOI: 10.2214/AJR.12.8999. View

20.

Watanabe R, Matsumura M, Munemasa T, Fujimaki M, Suematsu M . Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography: microscopic studies in rat liver. Invest Radiol. 2007; 42(9):643-51. DOI: 10.1097/RLI.0b013e31805f2682. View